書誌事項
- タイトル別名
-
- Identification of Patients with Type 2 Diabetes Mellitus Requiring Concentrated Pharmaceutical Management in Health Insurance Pharmacies:
- Quantitative Evaluation Using Administrative Claims Data
- レセプトデータを用いた定量的評価
この論文をさがす
説明
<p>The present nested case-control study aimed to clarify the type of patients with type 2 diabetes mellitus that required concentrated pharmaceutical management in health insurance pharmacies by detecting factors associated with the calculation of chouhukutouyaku-sougosayoutou-boushi-kasan. We detected the factors of patients on the JMDC claims database who met the eligibility criteria between April 1, 2018, and August 31, 2019, by using the multiple logistic regression model. For the analyses detecting the factors, 63,642 patients (case, 4,987; control, 58,655) were included. Regarding the calculation other than the adjustment of leftover drugs, 12 factors were statistically detected. Polypharmacy was most related to the calculation (odds ratio, 1.50; 95％ confidence interval, 1.35 - 1.66). The drugs concerned were mainly for lifestyle diseases (biguanides, dipeptidyl peptidase-4 inhibitors, glinides, glucagon-like peptide-1 agonists, alpha-glucosidase inhibitors, and hypolipidemic drugs). Regarding the calculation related to the adjustment of leftover drugs, 15 factors were statistically detected. Polypharmacy was most related to the calculation (odds ratio, 2.36; 95％ confidence interval, 2.02 - 2.76). The drugs concerned were mainly for non-lifestyle diseases (proton-pump inhibitors, H2 blockers, H1 blockers, antipsychotics, antidepressants, non-steroidal anti-inflammatory drugs, antimicrobial drugs, steroids, probiotics, and vitamins). Moreover, the increases in the detected factors positively possessed by the subject correlated with the calculations. The present study suggests, for patients with type 2 diabetes mellitus, that more attention should be paid to the interactions and duplicated prescriptions when increasing drugs for chronic diseases, and that more attention should be paid to leftover drugs when increasing drugs for temporary symptoms.</p>
収録刊行物
-
- 医療薬学
-
医療薬学 47 (1), 10-24, 2021-01-10
一般社団法人日本医療薬学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390572244891095808
-
- NII論文ID
- 130008140319
-
- ISSN
- 18821499
- 1346342X
-
- 本文言語コード
- ja
-
- 資料種別
- journal article
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
- KAKEN
- OpenAIRE
-
- 抄録ライセンスフラグ
- 使用不可
